Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in adolescents and young adults with B-lineage acute lymphoblastic leukemia
ACTRN12618001734257Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Oct 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Minimal residual disease negativity rate. Started Oct 2019; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12618001734257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001734257.